Species characterization and antifungal susceptibility profile of yeast isolates from blood cultures of fungemic patients in Thammasat University Hospital, Thailand
Article Sidebar
Main Article Content
Abstract
Background: Candida albicans is the most isolated fungal agent in a worldwide health system. Species distribution of Candida infection is different according to geographical regions. However, a shift in favor of non-albicans Candida species with antifungals resistance have increased as an important cause of candidemia.
Objectives: This study aimed to identify the species of yeasts isolated from the blood samples of patients at the university hospital and to determine in vitro susceptibilities of three most common isolates against nine antifungal agents.
Materials and methods:In total, 130 yeast isolates from 130 patients were defined the species using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Antifungal susceptibility testing was carried out using broth dilution Sensititre YeastOne panels included amphotericin B, 5-fucytosine, fluconazole, itraconazole, voriconazole, posaconazole, anidulafungin, micafungin, and caspofungin.
Results: The most common species in all age groups was C. tropicalis (n=48, 36.9%), followed by C. albicans (n=38, 29.2%). C. glabrata (n=23, 17.7%) was more common among elderly patients, while C. parapsilosis (n=9, 6.9%) was more frequently isolated from younger patients. Antifungal susceptibility testing in Candida species expressed MIC in the low level of almost antifungal drug except for reduced fluconazole susceptibility against C. glabrata and C. tropicalis isolates.
Conclusion: C. tropicalis is the most common infection in candidemic patients. Fluconazole resistance strains were found in C. glabrata and C. tropicalis, respectively. In addition, voriconazole resistance strains were found in C. tropicalis.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
Schroeder M, Weber T, Denker T, Winterland S, Wichmann D, Rohde H, et al. Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis. Ann Intensive Care. 2020; 10: 142.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010; 48(4): 1366-77.
Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Micro Rpt. 2015; 2: 84-95.
Naranong C, Anunnatsiri S, Srigulbutr S. Epidemiology and antifungal susceptibility in patients with candidemia in a University Hospital, Thailand. J Med Assoc Thai. 2020; 103(10): 1048-56.
Awad L, Tamim H, Abdallah D, Salameh M, Mugharbil A, Jisr T, et al. Correlation between antifungal consumption and the distribution of Candida species in different hospital departments of a Lebanese medical Centre. BMC Infect Dis. 2018 20; 18(1): 589.
Liu F, Zhong L, Zhou F, Zheng C, Zhang K, Cai J, et al. Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study. Infect Drug Resist. 2021; 14: 3233-46.
Wang H, Xu YC, Hsueh PR. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future Microbiol. 2016; 11: 1461-77.
Boonsilp S, Homkaew A, Phumisantiphong U, Nutalai D, Wongsuk T. Species Distribution, Antifungal Susceptibility, and Molecular Epidemiology of Candida Species Causing Candidemia in a Tertiary Care Hospital in Bangkok, Thailand. J. Fungi. 2021; 7(7): 577.
Hii IM, Liu CE, Lee YL, Liu WL, Wu PF, Hsieh MH, et al. Resistance rates of non-albicans Candida infections in Taiwan after the revision of 2012 Clinical and Laboratory Standards Institute breakpoints. Infect Drug Resist. 2019; 12: 235-40.
Linberg E, HammarstrÖm H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Scientific Reports. 2019; 9: 3838.
Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal Susceptibility Testing: current approaches. Clin Microbiol Rev. 2020; 30: 33: e00069-19. doi.org/10.1128/CMR.00069-19.
Wayne PA, Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts, 1st edition, CLSI document M60-Ed1. Clinical and Laboratory Standards Institute. 2017.
Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008; 14: 398-405.
Espinel-Ingroff A, Turnidge J, Alastruey-Izquierdo A, Botterel F, Canton E, Castro C, et al. Method dependent epidemiological cutoff values for detection of triazole resistance in Candida and Aspergillus species for the Sensititre YeastOne colorimetric broth and Etest agar diffusion methods. Antimicrob Agents Chemother. 2019; 63(1):e01651-18. Available from: https://doi.org/10.1128/AAC .01651-18.
Canton E, Pemán J, Hervás D, Iñiguez C, Navarro D, Echeverría J, et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cut off values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol, 2012; 50: 3921-6.
Ngamchokwathana C, Chongtrakool P, Waesamaae A. Risk Factors and Outcomes of Non-albicans Candida Bloodstream Infection in Patients with Candidemia at Siriraj Hospital— Thailand’s Largest National Tertiary Referral Hospital. J Fungi. 2021; 7: 269. doi.org/10.3390/jof7040269.
Wang H, Xu YC, Hsyeh PR. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future Microbiol. 2016; 11(11): 1461-77.
Faksri K, Kaekes W, Chaicumpar K, Chaimanee P, Wongwajana S. Epidemiology and identification of potential fungal pathogens causing invasive fungal infections in a tertiary care hospital in northeast Thailand. Med Mycol. 2014; 52(8): 810-8.
EI-Kholy MA, Helaly GF, EI Ghazzawi EF, EI-Sawaf G, Shawky SM. Virulence factors and antifungal susceptibility profile of C. tropicalis isolated from various clinical specimens in Alexandria, Egypt. J Fungi. 2021; 7(351): 1-11.
Tulasidas S, Rao P, Bhat S, Manipura R. A study on biofilm production and antifungal drug resistance among Candida species from vulvovaginal and bloodstream infections. Infect Drug Resist. 2018; 1(11): 2443-8.
Zuza-Alves DL, Silva-Rocha WP, Chaves GM. An update on Candida tropicalis based on basic and clinical approaches. Front Microbiol. 2017; 8(1927). Available from: https://doi.org/ 10.3389/ fmicb.2017.01927.
Tan BH, Chakrabarti A, Li RY, Patel AK, Watcharananan SP, Liu Z, et al. Asia Fungal Working Group (AFWG). Incidence and species distribution of candidaemia in Asia: A laboratory-based surveillance study. Clin Microbiol Infect. 2015; 21(10): 946-53.
Gupta A, Varma A. Candida glabrata candidemia: An emerging threat in critically ill patients. Indian J Crit Care Med. 2015; 19(3): 151-4.
Buranarom N, Komin O, Matangkasombut O. Hyposalivation, oral health, and Candida colonization in independent dentate elders. Plos One. 2020; 15(11). Available from: https://doi: 10.1371/journal.pone.0242832.
Charlet R, Pruvost Y, Tumba G, Istel F, Poulain D, Kuchler K, et al. Remodeling of the Candida glabrata cell wall in the gastrointestinal tract affects the gut microbiota and the immune response. Sci Rep. 2018; 8(3316).
Alenazy H, Alghamdi A, Pinto R, Daneman N. Candida colonization as a predictor of invasive candidiasis innon-neutropenic ICU patients with sepsis: A systematic review and meta-analysis. Inter J Infect Dis. 2021; 102: 357-62.
Hassan Y, Chew SY, Than LTL. Candida glabrata: Pathogenicity and resistance mechanisms for adaptation and survival. J Fungi. 2021; 7(8). Available from: https://doi: 10.3390/jof7080667.
Goemaere B, Lagrou K, Spriet I, Hendrickx M, Becker P. Clonal spread of Candida glabrata bloodstream isolates and fluconazole resistance affected by prolonged exposure: a 12-year single-center study in Belgium. Antimicrobial Agents Chemother. 2018; 62(8). Available from: https://doi: 10.1128/AAC.00591-18.
Yao D, Chen J, Chen W, Hu X. Mechanism of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist. 2019; 12: 771-81.
Wang, An N, Yang Y, Yang X, Fan Y, Feng J. Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression. Antimicrob Resist Infect Control. 2021. 10(1). Available from: https://doi:10.1186/s13756-021-00890-2 .
Kritikos A, Neofytos D, Khanna N, Schreiber PW, Boggian K, Bille J, et al. Fungal Infection Network of Switzerland (FUNGINOS). Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten-year national survey of the Fungal Infection Network of Switzerland (FUNGINOS). Clin Microbiol Infect. 2018; 24(1). Available from: https://doi:10.1016/ j.cmi.2018.05.012.